NKGen Biotech, Inc.’s Post

📣 Calling all DUBTAC, CyTAC, EpiTAC, PHICS and Molecular Glue Fanatics 📣 The long established 4th Induced Proximity-Based Drug Discovery Summit is returning to Bostin this July 23-25, 2024, to explore the emerging proximity phenomenon!! Check out the official event guide here 👉https://lnkd.in/er2TX2Bu Taking on knowledge gaps in validating novel mechanisms of action, accessing diverse chemical matter, and rationally designing selective and potent small molecules and biologics for novel target spaces, hear first-hand from pioneering leaders at Vicinitas Therapeutics, Gandeeva Therapeutics, Apertor Pharmaceuticals, TRIANA Biomedicines, Magnet Biomedicine, Photys Therapeutics, Rapafusyn Pharmaceuticals, Dana-Farber Cancer Institute, AstraZeneca, Genentech, AUTOTAC BIO Inc., Goethe University Frankfurt, Nurix Therapeutics, Kronos Bio, Solu Therapeutics, Broad Institute of MIT and Harvard, Lyterian Therapeutics, PAQ Therapeutics, EpiBiologics, Novartis and many more! To explore all expert-led talks, view the 2024 Agenda here👉https://lnkd.in/eNmryrhm 👈 #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC

📅 Add this to your 2024 calendar! 📅    Returning to Boston in July, the 4th Induced Proximity-Based Drug Discovery Summit will unite 100+ small molecule and biologics experts in the race to develop new stabilization, modulation, post-translational modification and inactivation/activation modalities for novel target spaces.  So, if your excited about DUBTACs, curious about PHICS, caught up on AUTOTACs or invested in the development of molecular glues or induced proximity biologics don't miss out on hearing the latest developments and innovations from Apertor Pharmaceuticals, TRIANA Biomedicines, Magnet Biomedicine, Photys Therapeutics, PAQ Therapeutics, Rapafusyn Pharmaceuticals, EpiBiologics, Gandeeva Therapeutics, Vicinitas Therapeutics, Novartis, Genentech, Dana-Farber Cancer Institute, Lyterian Therapeutics, Broad Institute of MIT and Harvard, AstraZeneca, Solu Therapeutics, AUTOTAC BIO Inc., Kronos Bio, Goethe University Frankfurt, Nurix Therapeutics, and many more! To explore all expert-led talks, view the 2024 Agenda here:  👉 https://lnkd.in/ec3JYh_q 👈  #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC

Save big and gain access to learnings even bigger, with savings of up to $1,100 on your pass for the 4th Induced Proximity-Based Drug Discovery Summit. Secure your seat amongst 80+ heterobifunctional, monovalent and biologics experts to hear the latest insights on: 🔴  Efficiently identifying & validating novel DUB Recruiters & DUBTACs with insights from Tyzoon Nomanbhoy, Vicinitas Therapeutics 🔴Developing induced proximity drugs with ADCs to demonstrate improved potency and selectivity with insights from Thomas Pillow, Genentech 🔴Leveraging CyTACs (Cytotoxicity Targeting Chimeras) to unlock GPCRs & Ion Channels with insights from Brandon Turunen, Solu Therapeutics 🔴Targeting mutant KRAS though precision modulation of protein phosphorylation with PHICS technology with insights from Moses Moustakim, Photys Therapeutics Not to mention experts from Kronos Bio, Rapafusyn Pharmaceuticals, Novartis Institute For Biomedical Research, Magnet Biomedicine, Dana-Farber Cancer Institute, EpiBiologics, Gandeeva Therapeutics and many more will all be sharing BRAND-NEW DATA! Check out the full event guide here: https://ter.li/4m8eg2 📣 Head to the online registration page to secure the early bird discount today or feel free to connect with me for more information! 📣 #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC

Augustine Therapeutics is proud to sponsor the 2024 Global CMT Research Convention, organized by the US CMT Research Foundation, to be held from September 26th to 28th 2024 at the Royal Sonesta Boston, Cambridge, MA. The event is gathering researchers, biotech and pharma companies, investors, and patients to discuss widely the latest research and development towards finding a cure for Charcot-Marie-Tooth patients. This yearly convention enhances the scope and possibilities of research discoveries as a step forward for the people who are living with CMT! In addition, our team will participate to the ‘Researcher Day’ on Friday, September 27th 2024: 🔵 Our Vice President Drug Discovery, Dr. Frederik Rombouts will be speaking at the session “Therapeutic Approaches That Target the Biology of CMT – 10:15 am EDT. Dr. Rombouts will provide an update on our first clinical candidate AGT100216 progressing towards First-in-man studies. AGT100216 is a peripheral-restricted selective, orally bioavailable and safe, non-hydroxamate and non-fluoromethyloxadiazole HDAC6 inhibitor. Title: ‘Developing Best-in-Class HDAC6 Inhibitors for the treatment of CMT1A’ 🔵 Our Executive Chair, Dr. Gerhard Koenig, will be panelist at the session gathering biotech Executive leaders on the theme “Understanding the criteria for pursuing a drug program for CMT” at 5:05 pm EDT. Dr. Koenig will highlight the groundbreaking science foundations of our HDAC6 program that emerged from the lab of Prof. Ludo Van Den Bosch at the VIB-KU Leuven, and the subsequent robust preclinical data in CMT studies that support our recently announced Series A1 round led by Asabys Partners, with the participation of Eli Lilly and Company, the CMT Research Foundation along our historical investors. ➡ Find out details of the event and agenda here: https://lnkd.in/giqRXt2F  #charcotmarietooth #cmtresearch #raredisease #drugdevelopment #healthcareinnovation #HDAC6 #GlobalCMTResearchConvention

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: September 25 - 26, 2024 (Get the full list of 30 news pieces in today's TLDR Biotech newsletter: https://lnkd.in/gKxuKwXw) • Bristol Myers Squibb’s historic schizophrenia FDA approval • ARCH Venture Partners $3B 13th fund • Genentech touts positive Ph3 Gazyva lupus data • CSL Seqirus nabs another BARDA bird flu contract • Mirai Bio launches as Flagship Pioneering’s newest endeavour • Novo Nordisk & Evotec partner to develop off-the-shelf stem-cell derived cell therapies • Inventiva Pharma’s coffers are weeks from running dry • Biogen and Sage Therapeutics discontinue essential tremor partnership • FDA adcomm advises narrower PD-1 inhibitor approvals • Top NIH neuroscientist conducted alleged widespread Parkinson’s & Alzheimer's research misconduct #biotech #pharma #pharmanews #biotechnews #tldrbiotech

KACTUS at Festival of Biologics 2024, Booth 517 📍 Mark your calendars! KACTUS is proud to sponsor America's Most Exciting Biologics Event: Festival of Biologics 2024. Join us in sunny San Diego at the San Diego Convention Center from April 15-17. 🔬 Presentation Spotlight: Don't miss out on the insights by Xiaoyuan Ran, our Director of R&D. Catch her talk on "Transforming Tumor Research: Engineering MHCs as Versatile Reagents" on April 15 at 3pm. 📊 Poster Presentations: Explore our innovative research through five engaging posters: #77: Transforming Tumor Research: Engineering MHCs as Versatile Reagents #78: GPCR VLPs & Nanodiscs for Drug Discovery #79: Tailored AAV Solutions: ELISA Kits and Customized Variant Kit Development #80: Enhancing Cell Therapy with GMP-Grade Cas9 Nuclease Exhibiting Superior Quality and Batch Consistency in Gene Editing #81: The Second-Generation High-Fidelity Cytosine Base Editor AccuBaseTM Can Proficiently Modify Multiple Genes Within A Human Primary T cell While Minimizing Off-target Effects For more details and to join us on this biologics voyage, click here: https://bit.ly/4cRcMdZ #KACTUS #festivalofbiologicsUSA #Biotech #Innovation #DrugDiscovery #antibodytherapeutics #antibodydiscovery

In the past two weeks, the biopharma industry has witnessed two multi-billion strategic partnerships fall apart as Sanofi cut half of its $6.2 billion deal with IGM Biosciences and Genentech terminated its T cell therapy partnership with Adaptimmune. This raises the question: what percentage of the BioBucks in a partnership deal actually get paid out, on average? Although companies rarely publish the unredacted deal terms of partnerships, nor do they publish which payments are actually made (unless material to a public company), nonetheless we can calculate the probability-adjusted expected value of the Sanofi-IGM and Genentech-Adaptimmune deals as shown below. I am using industry-typical probability of success by stage and am making rough guesses on how the milestones were distributed by stage. Such an expected value calculation can be thought of as answering the question: how much would the in-licensor expect to pay on average if they could conduct hundreds of experiments with these probabilities and deal terms. By the way, a more complete analysis would time-adjust the values with an NPV of cash flows but that is not shown here.   Sanofi-IGM deal was for 6 targets (3 cancer and 3 immunology/inflammation) with upfront of $150M and aggregate milestones of $940M per oncology target and $1,065M per immunology/inflammation target. Here is a rough cut at a probability-adjusted estimate of total payments to IGM Biosciences at the time the deal was signed, which at $909M is about 15% of the total BioBucks of $6.2B. #lifesciences, #businessdevelopment, #biotech

A beacon of precision in the dynamic world of biologics, STAT3 Monoclonal Antibody has been placed. Our STAT3 Monoclonal Antibody stands as a testament to innovation, designed to revolutionize therapeutic approaches by precisely targeting key signaling pathways. Elevate your research and therapeutic strategies with the unparalleled specificity and efficacy of our major discovery antibody. Excited to backpack on the transformative journey with GeNext Genomics, where breakthroughs become a reality. Explore the limitless potential of the STAT3 Monoclonal Antibody and witness the future of precision medicine unfold. . To Read More - https://lnkd.in/gXAd9Ace #GeNextGenomics #HighQualityBiologics #MonoclonalAntibody #STAT3Antibody #PrecisionMedicine 

Want to learn more about Evotec's capabilities in antibody discovery, combining in-depth understanding of disease biology and candidate derisking for developability and PK liabilities? Meet with me in sunny Montpellier

Want some insight into what's in store in the biotech industry in 2024? Ryght CEO Simon Arkell OLY recently participated in roundtable hosted by Genetic Engineering & Biotechnology News and moderated by Alex Philippidis where the panelists explored the issues that are driving their companies in the new year.   Listen in to Simon, Karen Zaderej, CEO of Axogen; and Neil McFarlane, CEO of Zevra Therapeutics here: https://lnkd.in/ecTvK3bz #2024predictions #biotech #genai